Dermavant Sciences, An Organon Company company information, Employees & Contact Information

Organon to Acquire Dermavant Sciences and Tapinarof Cream Dermatology Times

Dermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA National Eczema Association

Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama Fierce Pharma

Dermavant submits sNDA for tapinarof cream, 1% to treat AD in patients 2 years and up Contemporary Pediatrics

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% GlobeNewswire

Dermavant raises $200m to support tapinarof launch Pharmaceutical Technology

New Phase 3 Data Shows High Rate of Atopic Dermatitis Clearance Using Tapinarof Cream 1% HCPLive

Daily tapinarof use leads to 75% improvements in Eczema Area and Severity Index scores Healio

FDA Accepts Supplemental New Drug Application for Tapinarof Cream, 1%, in Atopic Dermatitis Pharmacy Times

Dermavant Announces New Positive Pruritus Data for VTAMA®(tapinarof) Cream, 1% in Adults and Children as Young as Two Years Old with Atopic Dermatitis at the EADV Congress 2023 National Eczema Association

Organon expands dermatology portfolio with Dermavant acquisition Pharmaceutical Technology

FDA Accepts Dermavant’s sNDA for Tapinarof Cream 1% for Adults and Children With AD Dermatology Times

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA Business Wire

FDA Accepts Tapinarof Cream sNDA for Atopic Dermatitis Patients Aged 2 Years and Older HCPLive

Organon to acquire Dermavant, Vtama cream in definitive agreement Healio

Fall Clinical: Long-term extension data of tapinarof cream 1% for atopic dermatitis Contemporary Pediatrics

Dermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older National Eczema Association

FORTUNE Names Dermavant One of the 2021 Best Workplaces in Health Care & Biopharma™ Business Wire

FDA Approves Tapinarof Cream, 1% for Atopic Dermatitis in Patients 2 Years and Older Dermatology Times

Dermavant Appoints Chris Chapman as Chief Commercial Officer GlobeNewswire

PDUFA Date for Tapinarof 1% Cream in Atopic Dermatitis Pushed to 2025 Dermatology Times

Organon Completes Acquisition of Dermavant New Jersey Business Magazine

FDA approves Vtama for topical psoriasis treatment Healio

Tapinarof cream 1% demonstrates positive topline results for treating pediatric AD Contemporary Pediatrics

Organon to acquire Dermavant in back-loaded deal The Pharma Letter

A Topical Treatment Revolution is on the Horizon for Psoriasis Healio

VTAMA effective against pediatric atopic dermatitis Contemporary Pediatrics

Dermavant’s AD drug not just making up the numbers The Pharma Letter

Dermavant Announces FDA Acceptance for Filing of New Drug Application (NDA) for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasis Business Wire

Dermavant reports positive long-term results for Vtama cream in atopic dermatitis PMLiVE

Dermavant launches first streaming commercial for new psoriasis treatment Vtama Fierce Pharma

With Vtama's success in relieving itching, Dermavant eyes FDA filing in atopic dermatitis Fierce Pharma

Roivant Deals Again, Sending Dermavant to Organon in Sale Worth Up to $1.2B BioSpace

Dermavant’s Todd Zavodnick is moving derm into the digital world Medical Marketing and Media

Dermavant CEO draws Botox comparison to instill Vtama confidence amid slow psoriasis uptake Fierce Pharma

FDA Accepts sNDA for Tapinarof Cream 1% for Treatment of Atopic Dermatitis Drug Topics

Dermavant posts data for Vtama that bolster its case for key approval in atopic dermatitis Fierce Pharma

New Topical Agents for Treatment of Plaque Psoriasis HCPLive

Brace for Breakthroughs in Psoriasis, Psoriatic Arthritis Dermatology Times

Dermavant looks to dethrone topical steroids with first FDA approval for Vtama in psoriasis Fierce Pharma

Dermavant’s Vtama receives FDA approval for plaque psoriasis PMLiVE

Key atopic dermatitis approvals are changing the treatment landscape Contemporary Pediatrics

Dermavant faces a perfect storm of pressures for tapinarof, but there is hope for the psoriasis drug Fierce Pharma

Dermavant hires CSO from GlaxoSmithKline, buys excessive sweating drug Fierce Biotech

Dermavant hires Todd Zavodnick as CEO Fierce Biotech

Dermavant inks $330M deal for GSK's phase 3-ready psoriasis drug Fierce Biotech

Organon: A Surprising Deal (NYSE:OGN) Seeking Alpha